Immunovaccine Inc., a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2 Study combining DPX-Survivac with Low …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
